Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 12:01 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1489–1512 of 1,745 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Formulation #2 Clear all

Conditions: Skin Inflammation
Interventions: Turmeric, Turmeric-containing combination tablet, Placebo tablets; Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years to 60 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Lennox Gastaut Syndrome
Interventions: Carisbamate; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 2 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 7
States / cities: Baltimore, Maryland • Lebanon, New Hampshire • Durham, North Carolina + 4 more

Conditions: Opioid-Related Disorders, Pain, Acute, Pain, Postoperative
Interventions: Norco 5Mg-325Mg Tablet, GRT7014 - Abuse Deterrent Tablet; Drug
Lead sponsor: Grünenthal GmbH; Industry
Eligibility: 18 Years to 55 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Lenexa, Kansas

Conditions: Heart Failure With Preserved Ejection Fraction, Low Triiodothyronine Syndrome
Interventions: liothyronine, Placebo; Drug · Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Castration-resistant Prostate Cancer, Metastatic Castration-sensitive Prostate Cancer, Metastatic Prostate Cancer
Interventions: TAVT-45, Zytiga, Prednisone; Drug
Lead sponsor: Tavanta Therapeutics; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 13
States / cities: Homewood, Alabama • Tucson, Arizona • Little Rock, Arkansas + 10 more

Conditions: Hypercholesterolemia
Interventions: Atorvastatin suspension, Lipitor; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Neovascular Age-Related Macular Degeneration
Interventions: GB-102, Aflibercept; Drug
Lead sponsor: Graybug Vision; Industry
Eligibility: 50 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 8
States / cities: Gilbert, Arizona • Beverly Hills, California • Indianapolis, Indiana + 5 more

Conditions: Hallux Valgus
Interventions: TLC590, Naropin®, Normal Saline, Bupivacaine; Drug
Lead sponsor: Taiwan Liposome Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 5
States / cities: Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 2 more

Conditions: Multiple Sclerosis
Interventions: Cladribine, Placebo, Rebif® new formulation (RNF); Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 617 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 24
States / cities: Phoenix, Arizona • Newport Beach, California • Denver, Colorado + 21 more

Conditions: Endothelial Function, Oxidative Stress, Inflamation, Vascular Health
Interventions: Cocoa Flavanol Supplement, Low-Flavanol Control Powder; Dietary Supplement
Lead sponsor: The Black Forest LLC; Industry
Eligibility: 30 Years to 75 Years · Male only
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Miami, Florida

Conditions: Schizophrenia
Interventions: Aripiprazole IM Depot; Drug
Lead sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 1,081 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 96
States / cities: Chandler, Arizona • Anaheim, California • Cerritos, California + 78 more

Conditions: Healthy
Interventions: CDB-2914, COB-2914; Drug
Lead sponsor: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); NIH
Eligibility: Female only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Pharmacokinetic Assessments in Healthy Volunteers
Interventions: PPI-668 capsule, PPI-668 tablet; Drug
Lead sponsor: Presidio Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Solid Tumors
Interventions: Wee-1 kinase inhibitor AZD1775; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 99 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 7
States / cities: Bingham Farms, Michigan • Detroit, Michigan • Lebanon, New Hampshire + 4 more

Conditions: Breast Cancer
Interventions: Trastuzumab emtansine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 153 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2013
U.S. locations: 15
States / cities: Fort Myers, Florida • Lafayette, Indiana • Scarborough, Maine + 11 more

Conditions: Muscle Performance, Sarcopenic Obesity
Interventions: IMM01-STEM, Placebo, IMM01-STEM alternating with placebo (saline); Biological · Other
Lead sponsor: Immunis, Inc.; Industry
Eligibility: 60 Years to 80 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 4
States / cities: Garden Grove, California • Pomona, California • Lenexa, Kansas + 1 more

Conditions: Influenza
Interventions: GSK A/turkey H5N1 Influenza vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 469 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Huntsville, Alabama • Anaheim, California • Miami, Florida + 4 more

Conditions: Influenza, Orthomyxoviridae Infections
Interventions: Influenza Virus Vaccine No Preservative: Pediatric Dose; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 6 Months to 5 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Solid Tumor
Interventions: RXDX-107; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 3
States / cities: Sarasota, Florida • Baltimore, Maryland • Nashville, Tennessee

Conditions: Skin Cancer
Interventions: Sunscreen, UV Light; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
Interventions: Alisertib, Pralatrexate, Gemcitabine, Romidepsin; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 271 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 24
States / cities: Birmingham, Alabama • La Jolla, California • Orlando, Florida + 21 more

Conditions: Chronic Lymphocytic Leukemia
Interventions: Treatment A, Treatment B, Treatment C, Treatment D, Treatment E, Treatment F, Treatment G, Treatment H, Treatment I, Treatment J; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Clinical High Risk for Psychosis, Ultra High Risk for Psychosis
Interventions: Stepped-Care including Cognitive Behavioral Case Management; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 12 Years to 25 Years
Enrollment: 223 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Elk Grove, California • Sacramento, California

Conditions: Healthy Participants
Interventions: S-892216-LAI, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Cypress, California • Lenexa, Kansas • Salt Lake City, Utah

Search by objective public record fields.

Turmeric and Turmeric-containing Tablets and Sebum Production

Carisbamate in Adult & Pediatric Subjects With Lennox-Gastaut Syndrome

A Comparison of Plasma Concentrations of Hydrocodone and Acetaminophen After Administration of a New and a Marketed Tablet Formulation Under Fasted and Fed Conditions in Healthy Adults

Developing Oral LT3 Therapy for Heart Failure - HFpEF

TAVT-45 (Abiraterone Acetate) Granules in Patients With Prostate Cancer

Bioavailability Study for New Atorvastatin Formulation

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration

A Study to Evaluate Safety, PK, Efficacy of TLC590 for Postsurgical Pain Management Following Bunionectomy

Oral Cladribine in Early Multiple Sclerosis (MS)

Black Forest Cocoa Flavanol Supplementation and Health Trial

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

Comparison of Blood Levels of Two Formulations of the Selective Hormone Receptor Modulator CDB-2914

Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations

AZD1775 Continued Access Study to Assess Safety and Tolerability for Patients Enrolled in AZD1775 Clinical Pharmacology Studies

A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer

Safety and Efficacy of IMM01-STEM Against Placebo on Muscle Performance in Seniors With Obesity and Muscle Weakness

Immunogenicity & Safety of GSK's Avian Flu Vaccine 1557484A Given to Adults Aged 18-64 Years

Annual Study for Serum Collection for Immunogenicity and Safety Evaluation in Healthy Children Receiving Fluzone®

Study of Intravenous RXDX-107 in Patients With Solid Tumors

Assessing a Natural Product Plus Bioadhesive Nanoparticle (BNP) Sunscreen

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

A Phase 1 Study of Novel GS-9973 Tablet Formulations to Evaluate the Effect of Acid Reducing Agents, Relative Bioavailability, and Food Effect on GS-9973 Pharmacokinetics

Sacramento Clinical High Risk for Psychosis Stepped-Care Program

Study of S-892216 Long-acting Injectable (LAI) in Healthy Adult Participants